Related Experiment Video
Updated: Jul 2, 2026
Microarray-based Identification of Individual HERV Loci Expression: Application to Biomarker Discovery in Prostate Cancer
Published on: November 2, 2013
[Identification and validation of clinically relevant molecular alterations in prostate cancer]
T Schlomm1, H Sültmann, J Köllermann
1Martini-Klinik, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland. tschlomm@uke.uni-hamburg.de
Abstract:
Significant cellular alterations required for the development and progression of cancers are detectable at the molecular level and represent potential targets for gene-specific therapies. Modern chip techniques allow the parallel analysis of virtually all known human genes and proteins in a single experiment. Using modern high-throughput techniques, numerous potential new biomarkers for the diagnosis and prediction of prostate cancer have been identified. However, so far none of these markers has improved clinical practice. One of the most important challenges in the coming years is the extensive clinical validation of molecular data using clinically relevant end points. For this venture the pivotal prerequisite is the availability of large, comprehensively annotated and standardized high-quality bioresources.
Insights
Molecular alterations in cancer are detectable and targetable. High-throughput techniques identify prostate cancer biomarkers, but clinical validation requires high-quality bioresources for improved patient care.
Area of Science:
- Oncology and Molecular Biology
- Genomics and Proteomics
Context:
- Cancer development and progression involve molecular alterations.
- High-throughput techniques enable parallel analysis of genes and proteins.
- Numerous potential prostate cancer biomarkers have been identified using these methods.
Purpose:
- To highlight the need for clinical validation of molecular biomarkers.
- To emphasize the importance of high-quality bioresources for advancing cancer research.
Summary:
- Significant cellular alterations in cancer are detectable at the molecular level.
- Modern chip and high-throughput techniques allow comprehensive gene and protein analysis.
- While new prostate cancer biomarkers are found, clinical validation is crucial and requires robust bioresources.
Impact:
- Facilitates the development of gene-specific cancer therapies.
- Aims to improve the diagnosis and prediction of prostate cancer.
- Stresses the necessity of large, standardized bioresources for clinical translation.
